Evaluation of the Safety and Efficacy of HSK39004 Dry Powder Inhaler and HSK39004 Inhalation Suspension in Chinese Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT07140328 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Obstructive Lung Disease (COLD)

Interventions

DRUG: HSK39004 Dry Powder Inhaler -0.75mg BID
DRUG: HSK39004 Dry Powder Inhaler -1.5mg BID
DRUG: HSK39004 Inhalation Suspension -3mg BID
DRUG: HSK39004 Placebo

Sponsor

Haisco Pharmaceutical Group Co., Ltd.